CCL15 and head and neck squamous cell carcinoma: Metformin sensitized HNSCC cells to gefitinib through the inhibition of CCL15 expression in M2-type TAMs and the suppression of CCR1 surface expression. These pathways are associated with resistance to gefitinib.